Project Number 1R44AG069622-01A1 Agency/Funding Organization NIA Funding Year 2021 View Full Project Details for A first-in-class orally bioavailable small molecule dual inhibitor targeting NLRP3 and the dopamine transporter to treat AD Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 4. Non-clinical Drug Development (small molecules and biologics) r. Multi-target Researcher and Organization Principal Investigator GABBITA, SOMASUNDAR PRASAD Principal Investigator First Name SOMASUNDAR PRASAD Principal Investigator Last Name GABBITA Awardee Organization P2D, INC. Awardee State Ohio Contact PI Country United States Project Detail Funding Opportunity Announcement PAS-19-316: Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional) FY Overall Cost $470,041 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official MARTIN, ZANE
